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A B S T R A C T   
Idiopathic pulmonary fibrosis (IPF) is the most common and most deadly form of interstitial lung disease. 
Osteopontin (OPN), a matricellular protein with proinflammatory and profibrotic properties, plays a major role 
in several fibrotic diseases, including IPF; OPN is highly upregulated in patients’ lung samples. In this study, we 
knocked down OPN in a bleomycin (BLM)-induced pulmonary fibrosis (PF) mouse model using small interfering 
RNA (siRNA) to determine whether the use of OPN siRNA is an effective therapeutic strategy for IPF. We found 
that fibrosing areas were significantly smaller in specimens from OPN siRNA-treated mice. The number of 
alveolar macrophages, neutrophils, and lymphocytes in bronchoalveolar lavage fluid was also reduced in OPN 
siRNA-treated mice. Regarding the expression of epithelial–mesenchymal transition (EMT)-related proteins, the 
administration of OPN-siRNA to BLM-treated mice upregulated E-cadherin expression and downregulated 
vimentin expression. Moreover, in vitro, we incubated the human alveolar adenocarcinoma cell line A549 with 
transforming growth factor (TGF)-β1 and subsequently transfected the cells with OPN siRNA. We found a sig-
nificant upregulation of Col1A1, fibronectin, and vimentin after TGF-β1 stimulation in A549 cells. In contrast, a 
downregulation of Col1A1, fibronectin, and vimentin mRNA levels was observed in TGF-β1-stimulated OPN 
knockdown A549 cells. Therefore, the downregulation of OPN effectively reduced pulmonary fibrotic and EMT 
changes both in vitro and in vivo. Altogether, our results indicate that OPN siRNA exerts a protective effect on 
BLM-induced PF in mice. Our results provide a basis for the development of novel targeted therapeutic strategies 
for IPF.   
1. Introduction 
Idiopathic pulmonary fibrosis (IPF), one of the most common inter-
stitial lung diseases, is characterized by alveolar epithelial cell injury, 
extensive fibroblast proliferation, extracellular matrix accumulation in 
the lung, and irreversible decline in lung function [1]. The incidence of 
IPF in North America and Europe is 3–9 cases per 100,000 person-years 
[2]. The prognosis for patients with IPF is poor, and the median survival 
of patients with IPF is only 3–5 years [2,3]. Recently, pirfenidone and 
nintedanib have been used in the treatment of IPF patients; however, the 
treatment of IPF and disease survival rates have not significantly 
changed [4,5]. Strong side effects such as diarrhea, vomiting, weight 
loss, and loss of appetite have been reported for these drugs [6]. Ac-
cording to the American Thoracic Society and the European Respiratory 
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Society, aside from oxygen therapy and lung transplantation, there are 
no other proven curative therapies for IPF [7]. 
Small interfering RNA (siRNA), which can attain target-specific gene 
silencing, may be a potent tool for gene therapy [8]. A large number of in 
vitro and in vivo preclinical studies and recent clinical trials have 
demonstrated the therapeutic effects of siRNA and provided a 
completely different direction to conventional treatment methods [9]. 
The use of siRNA provides new hope for patients, and clinical trials with 
siRNA are currently underway for various diseases [10]. Many studies 
that propose the use of siRNA in certain lung diseases continue to be in 
the preclinical, phase 1, phase 2 and phase 3 stages [11]. However, thus 
far, no studies have targeted the osteopontin (OPN) gene in vivo with 
siRNA for the treatment of IPF. There are several ways to deliver siRNA 
into the patient’s system. Intranasal administration of siRNA has been 
demonstrated to be an effective way for delivering siRNA [12] as we 
carried out in this study. 
Epithelial–mesenchymal transition (EMT) is a process in which 
epithelial cells lose epithelial proteins and recent findings suggest that it 
may be one possible etiology of IPF, mediated by transforming growth 
factor beta(TGF)-β1 [13,14]. 
OPN has been shown to have both proinflammatory and profibrotic 
properties, and some studies have reported the increased expression of 
OPN in mouse models of pulmonary fibrosis and patients with chronic 
lung diseases such as IPF [15]. However, it is still unknown whether 
OPN siRNA can improve pulmonary fibrosis and EMT both in vivo and in 
vitro. 
In this study, we investigated whether OPN participates in either 
TGF-β1- (in vitro) or BLM-induced gene regulation (in vivo) in pulmonary 
EMT or fibrosis and whether this function contributes to increased 
fibrosis in IPF. We also examined the effects of OPN RNA silencing in a 
BLM-induced IPF mouse model and an in vitro TGF-β1-induced EMT 
model. 
2. Materials and methods 
2.1. Materials 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) unless otherwise specified. Recombinant human TGF-β1 was 
purchased from R&D Systems (Minneapolis, MN, USA). Bleomycin was 
purchased from Nippon Kayaku (Tokyo, Japan). We obtained siRNA 
DharmaFECT™ and siRNA Transfection Reagent from Dharmacon 
(Lafayette, CO, USA). Anti-E-cadherin (ab11512), anti-vimentin 
(ab92547), anti-collagen I (ab21286), and anti-fibronectin (ab2413) 
antibodies were purchased from Abcam Ltd. (Cambridge, UK). A mouse 
monoclonal antibody against β-actin (A2228) was purchased from 
Sigma-Aldrich (Taufkirchen, Germany). Anti-phospho-p38 (#9211), 
p38 MAPK antibody (#9212), phospho-Smad 2/3 (#8828), and total 
Smad 2/3 (#8685) were obtained from Cell Signaling Technology, Inc. 
(Danvers, MA, USA). Rabbit anti-mouse immunoglobulin-horse radish 
peroxidase (HRP), rabbit anti-goat immunoglobulin-HRP, and goat anti- 
rabbit immunoglobulin-HRP were purchased from Dako UK Ltd. (Cam-
bridgeshire, UK). Protease inhibitor cocktail was obtained from Roche 
Diagnostics Ltd. (Sussex, UK). The BCA protein assay kit was purchased 
from Thermo Fisher Scientific (San Jose, CA, USA). Polyvinylidene 
difluoride (PVDF) membranes were obtained from GE Healthcare UK 
Ltd. (Amersham, Buckinghamshire, UK). TRIzol for RNA extraction was 
obtained from Invitrogen (Carlsbad, CA, USA). The Takara RNA PCR kit 
was purchased from Takara Shuzo Co., Ltd. (Shiga, Japan). Sequences of 
siRNAs and quantitative reverse transcription-polymerase chain reac-
tion (RT-qPCR) primers used in the study are shown in Table 1. 
2.2. Animals 
We used 8–10-week-old C57/BL6 male mice in this study, who were 
maintained in an accredited, specific pathogen-free, and environmen-
tally controlled facility at the Animal Facility Center of Dişkapi Yildirim 
Beyazit Training and Research Hospital. This study was approved by the 
Dişkapi Yildirim Beyazit Training and Research Hospital, Ankara, 
Turkey under registration number 2013/21. All protocols involving 
experimental animals followed the local institutional guidelines for 
animal care, which are comparable to those in the “Guide for the Care 
and Use of Laboratory Animals” published by the Institute for Labora-
tory Animal Research (National Institutes of Health Publication No. 
8023, revised 1978). 
2.3. Bleomycin-induced pulmonary fibrosis and administration of siRNAs 
in vivo 
The fibrotic models used in this study are the popular BLM-induced 
pulmonary fibrosis mouse models. All animals were divided randomly 
into three groups: the (a) saline (b) BLM + scramble siRNA and (c) BLM 
+ OPN siRNA groups. To facilitate BLM administration, animals were 
anesthetized with an intraperitoneal injection of pentobarbital sodium 
(50 mg/kg) and then administered 2 U/kg BLM dissolved in 50 μL sterile 
isotonic saline through the intratracheal route using a 22 G plastic 
Table 1 
Sequence of sense siRNA and qPCR primers.  
Target Species Forward (5’–3’) Rewerse (5’–3’) 
Primers for qPCR    
E-cadherin Human TATTCCTCCCATCAGCTGCC CTGTCACCTTCAGCCATCCT 
COL1A1 Human GTGACGAGACCAAGAACTGC CTGTCCAGGGATGCCATCTC 
OPN Human CAGCCAGGACTCCATTGACT ACACTATCACCTCGGCCATC 
Fibronectin Human AGAATGTCAGCCCACCAAGA GCTTCTGACATCTGGCTTGA 
Vimentin Human GCTTCGCCAACTACATCGAC TTGTCGTTGGTTAGCTGGTC 
GAPDH Human GAAGGTGAAGGTCGGAGTCA TGACAAGCTTCCCGTTCTCA 
E-cadherin Mouse GAATGACAACAGGCCAGAGT CAGCGTTGTAGGTGTTGACG 
Vimentin Mouse TGAAGGAAGAGATGGCTCGT TTGAGTGGGTGTCAACCAGA 
IL-6 Mouse AGCCAGAGTCCTTCAGAGAGA GGATGGTCTTGGTCCTTAGCC 
Fibronectin Mouse GAAGAGTGAGCCCCTGATTG TCATACCCAGGGTTGGTGAT 
GAPDH Mouse CATGGCCTTCCGTGTTCCTA TGCCTGCTTCACCACCTTCT 
siRNA (Pool)  siRNA sequence 
OPN Human CCAAGUAAGUCCAACGAAA   
CAUCUUCUGAGGUCAAUUA   
UGAACGCGCCUUCUGAUUG   
GAUGAACUGGUCACUGAUU 
OPN Mouse CAGUCGGAUGUGAUCGAUA   
CCACAUGGACGACGAUGAU   
CGGAUGAAUCUGACGAAUC   
GAUCAGGACAACAACGGAA  
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cannula. Sterile saline was administered to control mice. Next, on day 3 
and 7 after BLM injection, mice with pulmonary fibrosis were intrana-
sally injected with either saline and scramble siRNA or OPN siRNA (2 
mg/kg), which was dissolved in diethylpyrocarbonate (DEPC)-treated 
water mixed with DharmaFECT™ siRNA transfection reagent, to a total 
volume of 50 μL. On day 14 after BLM administration, the mice were 
sacrificed; then, lung tissue and 1.5 mL bronchoalveolar lavage fluid 
(BALF) (0.9% saline, administered through a tracheal cannula, was used 
to lavage the mouse lungs three times) was collected from each mouse 
for the experiments (Supplemental Fig. 1A). 
2.4. Histological analysis 
Histological analysis was performed as previously described [16]. 
The lung tissue samples were fixed in 4% formalin and embedded in 
paraffin. Paraffin Section (5 µm thick) were obtained from the fixed 
lungs and stained with hematoxylin and eosin (HE), Masson’s trichrome 
(MT), and picrosirius red (PSR) (Polysciences Inc., Warrington, PA, 
USA) stain to determine fibrosis. Lung fibrosis was measured using 
quantitative histology following Ashcroft’s method [17], and the per-
centage of alveolar air area was calculated as described previously [18]. 
The tissue sections were examined under a Biozero BZ-X700 microscope 
(KEYENCE, Tokyo, Japan) at the Central Research Laboratory, Okayama 
University Medical School, Japan. 
2.5. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) and western blotting 
Western blotting was performed as described previously [19]. 
Briefly, the cells or lungs were washed once in phosphate buffer saline 
(PBS) and collected by scraping into a 100 μL ice-cold mixture of 50 mM 
HEPES, 100 mM sodium fluoride, 2 mM sodium orthovanadate, 4 mM 
ethylenediaminetetraacetic acid (EDTA), 1% Tween-20, 0.1% SDS, and 
a complete protease inhibitor, and then incubated on ice for 30 min. The 
supernatant was collected after centrifugation at 13,000×g for 15 min at 
4 ◦C. Total protein concentration was measured using the BCA protein 
assay kit with bovine serum albumin as the standard protein. The pro-
tein preparations were mixed with 4X Laemmli loading buffer and 
heated to 95 ◦C for 5 min. Protein samples (15 μg/well) were loaded for 
each lane of 10% SDS–PAGE gels, followed by electrophoresis, and 
transferred to PVDF membranes. After blocking with 5% skim milk in 
Tris-buffered saline (TBS) for 1 h, the membranes were incubated 
overnight at 4 ◦C with primary antibodies in TBS containing 0.05% 
Tween-20, followed by incubation with HRP-conjugated secondary 
antibody. β-actin was used for the control loading. Bands were evaluated 
using densitometry and the ImageJ software. 
2.6. Quantitative reverse transcription-PCR 
We extracted RNA with TRIzol as previously described [20,21]. 
Briefly, the samples were washed three times in PBS. Total RNA was 
separated from DNA and proteins by adding chloroform and precipitated 
using isopropanol. The precipitate was washed in 70% ethanol, 
air-dried, and re-diluted in DEPC-treated distilled water. The RNA 
quality and concentrations were determined using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). For 
RT-PCR, the Takara RNA PCR kit was used as follows: 30 ◦C for 10 min; 
42 ◦C for 50 min; and 90 ◦C for 5 min. The thermal cycling conditions 
were 10 min at 30 ◦C, 60 min at 42 ◦C, 5 min at 90 ◦C, and finally held at 
4 ◦C. The mRNA expression levels of target genes were quantified using 
RT-PCR (ABI Prism 7700; Applied Biosystems, Waltham, USA) using the 
comparative 2-ΔΔCT method as previously described [22,23]. 
2.7. Cell culture and transfection of synthetic siRNA 
The A549 cells were maintained in low glucose-Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10% FBS, 100 U/mL peni-
cillin, and 100 μg/mL streptomycin and incubated at 37 ◦C in a hu-
midified atmosphere containing 5% CO2 and 95% air, as previously 
described [24,25]. For transfection, the cells were seeded at 2 × 105 
cells/well of six-well plates, incubated in normal medium without an-
tibiotics overnight, and transfected with 25 nM siRNA in Opti-MEM 
using DharmaFECT reagent according to the manufacturer’s in-
structions, together with a nonspecific control pool of siRNA as negative 
control. 
2.8. Statistical analysis 
Statistical analysis was performed using the SPSS 11.5 statistical 
software. The Student’s t-test was used to analyze differences between 
the two groups. We considered P < 0.05 as statistically significant. 
3. Results 
3.1. Osteopontin siRNA protects against BLM-induced lung fibrosis and 
ameliorates IL-6 induction 
To determine whether OPN siRNA has an antifibrotic effect on BLM- 
induced pulmonary fibrosis in mice, we carried out histological analysis 
of their tissue specimens and evaluated their BALF, as BLM-induced lung 
fibrosis is accompanied by an accumulation of BALF cells (eosinophils, 
macrophages, and neutrophils). OPN expression increased significantly 
in the BLM-injected mouse groups compared to that in the control group. 
When the expression of OPN was downregulated by siRNA, OPN 
protein expression levels significantly decreased compared to those in 
the control group (Fig. 1A). The optimal siRNA concentration (2 mg/kg) 
was determined in the pilot experiment (Supplemental Fig. 4). The body 
weight of BLM-scramble siRNA mice gradually decreased, whereas BLM- 
OPN siRNA mice maintained their body weight (Supplemental Fig. 1B). 
We examined the in vivo antifibrotic effects of OPN-siRNA on BLM- 
induced fibrosis by using HE, MT, and PSR staining. As shown in 
Fig. 1B, the alveolar walls were severely thickened and diffuse in-
filtrations of inflammatory cells were evident in the pulmonary inter-
stitium in response to BLM administration. Conversely, the fibrosing 
areas were significantly smaller in specimens from OPN siRNA-treated 
mice than in those from other control groups. The macroscopic 
appearance of the lungs indicated that OPN siRNA protected against 
BLM lung damage (Supplemental Fig. 1C). Furthermore, MT and PSR 
staining showed that collagen deposition in the alveolar septum of OPN 
siRNA-treated mice was reduced compared to that in control siRNA 
mice. The grade of fibrosis was significantly decreased in OPN-siRNA- 
treated mice, as evidenced by the Ashcroft score, whereas that of the 
scramble siRNA-treated mice was markedly increased (Fig. 1C). In 
addition, BLM induced the loss of air space, but OPN siRNA blocked the 
loss of air space (Fig. 1D). Moreover, interleukin-6 (IL-6) plays an 
important role in IPF [26]. We found that the significant increase in 
fibrosis-related cytokine IL-6 levels in lung tissues with 
bleomycin-induced pulmonary fibrosis and IL-6 levels were dramatically 
reduced by OPN siRNA in BLM-treated mice (Fig. 1E). 
3.2. Osteopontin siRNA administration ameliorates the number of 
immune cells in BALF 
The total number of BALF cells increased after BLM administration. 
The total number of BALF cells from OPN siRNA mice was significantly 
lower than that in scramble siRNA mice. Furthermore, the number of 
alveolar macrophages, neutrophils, and lymphocytes in BALF was 
reduced in OPN siRNA-treated mice compared with that in the control 
mice (Fig. 2). 
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Fig. 1. OPN siRNA attenuates pulmonary fibrosis in BLM-induced pulmonary fibrosis model mice. (A) Increased OPN expression levels in BLM-treated mouse lung 
tissues collected on day 14. Western blot analysis assessment revealed that upregulation of OPN expression was successfully suppressed by OPN siRNA (n = 3). (B) 
Histological analysis of mouse lung tissue. Representative images of Hematoxylin and Eosin (HE)-, Masson’s Trichrome (MT)-, and Picrosirius Red (PSR)-stained lung 
sections obtained on day 14. Scale bar = 100 µm. Fibrosing areas were significantly ameliorated in specimens from the OPN-siRNA treated mice than in specimens 
from BLM-scramble siRNA groups. Degrees of pulmonary fibrosis were scored and evaluated using (C) Ashcroft’s method and (D) alveolar air area percentage (n = 5). 
(E) IL-6 mRNA expression in mouse lung tissues. Data are represented as mean ± SEM. Statistical analysis was carried out using the Student’s t-test. P < 0.05 was 
considered statistically significant (**p < 0.01, *p < 0.05). 
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3.3. Osteopontin inhibition attenuates EMT in BLM-treated mice 
Next, we examined the expression of EMT-related genes in the lung. 
The results of the RT-PCR and western blot analysis both indicated that 
the expression of E-cadherin (epithelial marker) decreased, whereas the 
expression levels of vimentin and fibronectin (mesenchymal markers) 
increased with BLM stimulation (Fig. 3A). When the expression of OPN 
was downregulated by siRNA, it increased the expression of E-cadherin 
protein and decreased the expression of vimentin (Fig. 3B). The graphs 
in Fig. 3C and D show the density of each band normalized to β-actin for 
E-cadherin and vimentin, respectively. 
3.4. In vitro OPN inhibition attenuates TGF-β1-dependent EMT activation 
via Smad signaling 
We examined how OPN shows its effect on fibrosis and EMT path-
ways in A549 cells. 
The mRNA expression of the epithelial marker E-cadherin signifi-
cantly decreased (Fig. 4A) in a dose-dependent manner (Supplemental 
Fig. 2A) in the scramble siRNA mice. In contrast, the mRNA expression 
of the mesenchymal marker vimentin increased (Fig. 4B and Supple-
mental Fig. 2B) indicating that EMT was induced by TGF-β1 stimulation. 
In addition, the downregulation of OPN by siRNA led to the recovery of 
E-cadherin mRNA, and the expression levels of vimentin mRNA were 
attenuated compared to those in scramble siRNA. To further evaluate 
the antifibrotic effects of OPN siRNAs on A549 cells, collagen, fibro-
nectin, and vimentin expression was measured using RT-PCR. We 
confirmed a significant upregulation of Col1A1, fibronectin, and 
vimentin (Fig. 4B) by TGF-β1, whereas siRNAs of OPN reduced the 
collagen, fibronectin, and vimentin mRNA expression. 
Next, we examined the expression of fibrosis-related genes in A549 
cells by western blotting. The protein expression levels of Col1A1 and 
fibronectin were significantly increased and that of E-cadherin 
decreased in response to TGF-β1 stimulation. However, OPN siRNA 
markedly restored the protein expression levels of fibrotic genes to a 
normal level (Fig. 4C, D). 
Furthermore, we investigated whether the Smad 2/3 and p38 
signaling pathways were involved in the antifibrosis effect of OPN 
siRNA. We found that TGF-β1 altered the expression levels of fibrosis- 
related genes and EMT-related genes in A549 cells through the Smad 
2/3 and p38 signaling pathways. In addition, downregulation of the 
OPN expression by siRNA led to the inactivation of Smad 2/3 and p38 
signaling pathways (Fig. 4E, F). These data suggest that the antifibrotic 
effect of OPN siRNA may be mediated by the inhibition of TGF-β1/Smad 
Fig. 2. Effect of OPN siRNA on the infiltration of total and differential cell 
counts in BALF on day 14 (n = 5–6). Data are represented as mean ± SEM. 
Statistical analysis was carried out using the Student’s t-test. P < 0.05 was 
considered as statistically significant (**p < 0.01, *p < 0.05). 
Fig. 3. Effects of OPN siRNA on E-cadherin and vimentin expression in mouse 
models. (A) E-cadherin and vimentin mRNA and (B) protein expression in 
mouse lung tissues. (C and D) Western blotting analysis reveals a decrease in E- 
cadherin (epithelial marker) and concomitant increase in vimentin (mesen-
chymal marker). β-actin served as loading control for western blotting (n = 3). 
Data are represented as mean ± SEM. Statistical analysis was carried out using 
the Student’s t-test. P < 0.05 was considered statistically significant 
(**p < 0.01, *p < 0.05). 
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signaling pathway. 
Finally, we performed western blotting to examine whether OPN 
expression was upregulated with TGF-β1 stimulation in an in vitro 
model. Western blot analysis showed that TGF-β1 enhanced the protein 
level of OPN. When the expression of OPN was downregulated by siRNA, 
OPN protein expression levels significantly decreased compared with 
those in the control group (Supplemental Fig. 3). 
4. Discussion 
In this study, we examined the effects of OPN RNA silencing in a 
BLM-induced IPF mouse model and an in vitro TGF-β1-induced EMT 
model. The accumulation of lung collagen and infiltration of 
inflammatory cells in BALF caused by BLM were significantly attenuated 
by OPN siRNA. The impact of OPN siRNA was confirmed by the inhi-
bition of EMT in A549 cells. Our data indicated that silencing of OPN 
attenuated lung fibrosis in BLM-induced IPF model; thus, OPN silencing 
is a promising therapeutic option for IPF. 
IPF is a progressive disease with high mortality rate. Overall, the 
mean survival rate of IPF patients from its initial diagnosis is approxi-
mately 3 years [27]. There are several risk factors such as smoking and 
potential viral infections (e.g., Epstein–Barr Virus and Herpes simplex 
virus) [1,28] that are associated with IPF. However, the definitive eti-
ology is still under investigation. In this study, we demonstrated that 
OPN was upregulated in a BLM-induced IPF model. In clinical IPF, OPN 
mRNA expression is upregulated [15]. It has also been reported that 
Fig. 4. Analysis for the effect of OPN siRNA on lung fibroblast differentiation and p38, Smad 3/4 signaling after TGF-β1 stimulation. Following the transfection of the 
A549 cells with the OPN siRNA and TGF-β1 treatment, RT-PCR analysis revealed the expression of (A) E-cadherin, (B) vimentin, COL1A1, and fibronectin. The 
expression levels were normalized against GAPDH mRNA (n = 5). Data are represented as mean ± SEM. Statistical analysis was carried out using the Student’s t-test. 
P < 0.05 was considered statistically significant (*P ≤ 0.05 versus control, #P ≤ 0.05 versus scramble siRNA group). The relative expressions of E-cadherin, 
fibronectin, and COL1A1 proteins were determined using western blotting (C and D). The activation of p-p38/p38 and p-Smad 3–4/Smad 3–4 protein levels following 
transfection of the A549 cells with the OPN siRNA and TGF-β1 treatment were determined by western blotting. β-actin was used as a loading control (E and F) 
(n = 3). Data are represented as mean ± SEM. Statistical analysis was carried out using the Student’s t-test. P < 0.05 was considered as statistically significant 
(*P ≤ 0.05 versus control, #P ≤ 0.05 versus scramble siRNA group). 
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serum OPN levels were increased in IPF patients, and the serum level of 
OPN was linked with acute exacerbation of IPF [29]. These data indicate 
that OPN is a biomarker for IPF, and our data further support that OPN 
expression is closely associated with the progression of lung fibrosis in 
IPF. 
Inhibition of lung fibrosis is the key target for the treatment of IPF, 
because fibrotic change is considered irreversible. The prognosis of IPF 
worsens in accordance with fibrotic changes. OPN has been reported to 
be associated with tissue fibrosis [30]. In addition, it has been reported 
to promote the acetylation of the intracellular high-mobility group box-1 
(HMGB1) in hepatic stellate cells and activate the PI3K-pAkt1/2/3 
pathway, which results in the increased production of type I collagen 
[31]. OPN contains several functional domains, such as the RGD 
domain. Integrin αvβ3 has been shown to interact through the RGD 
domain [32,33]. Arriazu et al. reported that OPN also binds to integrin 
αvβ3 and activates the PI3K-Akt-IkB-NFkB signaling pathway [34]. 
Moreover, OPN binds to αvβ6 integrin [35]. Integrin αvβ6 is minimally 
expressed in alveolar epithelial tissues but is highly induced upon lung 
injury, resulting in lung fibrosis. Integrin αvβ6 has been demonstrated to 
be overexpressed in the epithelium of patients with lung sclerosis and 
pulmonary fibrosis. Horan et al. reported that the partial inhibition of 
integrin αvβ6 can effectively inhibit TGF-β activation, epithelial injury, 
and tissue fibrosis in a murine model of BLM-induced IPF [36]. Munger 
et al. reported the knockdown of integrin β6 in mice to attenuate 
BLM-induced pulmonary fibrosis and radiation-induced pulmonary 
fibrosis [37]. Popov et al. reported that integrin β6 correlates with the 
stage of fibrosis in the livers of patients with end-stage liver disease, 
including chronic hepatitis B and C, primary biliary cholangitis (PBC), 
and primary sclerosing cholangitis (PSC) [38]. Although we did not 
examine the distribution of integrin αvβ6 in our IPF model, the inter-
action of OPN with integrin αvβ6 was suggested in these previous 
studies. The interaction between OPN and integrin αvβ6 was disturbed 
by OPN silencing, and this may have resulted in the attenuation of lung 
fibrosis in the BLM-induced IPF model. 
Notably, our results demonstrated that OPN silencing significantly 
attenuated inflammatory cell infiltration in BALF. Macrophages have 
been reported to play a role in IPF. Leach et al. reported that endothelial 
cells facilitate the development of BLM-induced fibrosis through several 
different mechanisms, contributing to both inflammatory and fibrotic 
processes. Lund et al. reported that OPN induced inflammatory cell 
migration and thus mediated chronic inflammation [39]. They also re-
ported that OPN regulates the immune system at different molecular 
levels (e.g., intracellular and extracellular). In this regard, our results 
revealed that OPN silencing can effectively attenuate inflammatory re-
actions by protecting against infiltration of inflammatory cells in 
BLM-induced IPF models, although the anti-inflammatory molecular 
mechanism has not been clarified. 
Our data demonstrated that silencing of OPN protected from fibrotic 
changes in BLM-induced IPF model in mice. Notably, this change was 
accompanied by the inhibition of EMT, which is also known to play a 
role in tumorigenesis [40,41]. Interestingly, EMT also plays a role in 
fibrosis [42]. It induces extracellular matrix production, such as 
collagen, and results in the progression of tissue fibrosis. Recently, EMT 
alteration has been a found to be a probable event that causes IPF, and 
EMT plays an important role in the development of IPF [43,44]. 
EMT is a pathophysiological process in which epithelial cells lose 
some of their characteristics and markers, including reduced expression 
of E-cadherin and enhanced expression of vimentin and N-cadherin 
while showing mesenchymal cell phenotypes. TGF-β1 has been shown to 
have key roles in pulmonary fibrosis through induction of EMT in 
alveolar epithelial cells by activating Smad pathways [45]. OPN has also 
been demonstrated to induce EMT, and several studies have explored 
this relationship [46,47]. Twist, ZEB, and Snail are the major regulator 
proteins for EMT, and these molecules have been reported to be regu-
lated by OPN [46]. Although we did not primarily focus on the 
involvement of these regulatory molecules in this study, OPN silencing 
attenuated the phosphorylation of the Smad and p38 signaling path-
ways. Therefore, we consider that OPN silencing affects EMT regulatory 
molecules (such as Twist, ZEB, and Snail). The precise underlying 
mechanism will be examined in a future study. 
Our data demonstrated that collagen was increased by TGF-β1 at 
both mRNA and protein levels. Although we did not examine the content 
of hydroxyproline, many previous studies have demonstrated that hy-
droxyproline was also increased by TGF-β1 in various cells, including 
A549 cells [48]. Thus, it can be suggested that hydroxyproline content 
was also affected by OPN siRNA. Timur et al. reported that OPN 
enhanced lung fibrosis by promoting TGF-β1 activation, and it may act 
upstream of TGF-β1 [49]. Another study showed that OPN plays various 
roles in pulmonary fibrosis, including stimulation of expression and 
activation of TGF-β1 and induction of fibroblast-to-myofibroblast dif-
ferentiation. A lack of OPN attenuated TGF-β1 signaling in the lung and 
reduced pulmonary fibrosis. OPN has been found to be involved in the 
induction and activation of TGF-β1 signaling in vivo and in vitro. More-
over, it has been shown that OPN exerts its pro-fibrotic effects by 
regulating fibroblast and myofibroblast functions through the TGF-β1 
pathway [50]. These data strongly support the idea that OPN activates 
the TGF-β1 signaling pathway. 
This is the first study to apply OPN RNA silencing in an IPF model. 
Although RNA silencing is a mechanism for controlling the target gene, 
it has never been examined for the treatment of IPF. This method has 
been approved as a clinical “drug” for a rare inherited disease (heredi-
tary transthyretin-mediated amyloidosis; hATTR amyloidosis). Pati-
siran, targeting the 3′-untranslated region of transthyretin mRNA, has 
been reported to reduce the mutant (and wild type) transthyretin protein 
level [51]. It achieved successful results in the third phase clinical trial 
[52] and was finally approved by the Food and Drug administration in 
2018. In addition, there are various ongoing trials using RNA silencing 
for cancer therapy. For example, OPN knockdown suppresses the growth 
and angiogenesis of colon cancer cells [53]. Other researchers also re-
ported that OPN silencing suppresses angiogenesis in endometrial can-
cer in vitro and in vivo [54] and reduces liver metastasis in a human 
pancreatic cancer xenograft model [55]. Therefore, RNA silencing 
therapy will become a popular option for various diseases in the future, 
including IPF. Our study sheds light on the challenge of preventing lung 
fibrosis and inflammatory cell infiltration accompanied by the inhibition 
of EMT in IPF. 
However, this study also has a limitation. It is essential that the effect 
of OPN silencing does not cause harm to other organs. We did not 
examine the effect of OPN silencing on other organs assuming that the 
local administration of the drug to the lung will have a limited effect on 
other organs. 
In conclusion, OPN is a multifunctional protein that plays an 
important role in the pathogenesis of IPF (Fig. 5. Graphical abstract); 
thus, OPN silencing is a promising strategy for IPF therapy. 
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